CTOs on the Move

SAB Biotherapeutics

www.sabbiotherapeutics.com

 
SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
David Miller
 Senior Director of Information Technology and Security Profile

Funding

SAB Biotherapeutics raised $22M on 12/20/2018
SAB Biotherapeutics raised $14M on 07/17/2020

Similar Companies

Western Slope Labs

Western Slope Labs is a Troy, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Znomics

Znomics is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tel-Drug

Tel-Drug is a Sioux Falls, SD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ABC Laboratories

Analytical Bio-Chemistry (ABC) Laboratories, Inc. is a GLP and CGMP-compliant contract laboratory with expertise in analytical services and radiolabeling synthesis. From its inception in 1968, ABC Laboratories has been dedicated to solving scientific

BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.